Table 3. Prognostic factors other than... | American Society of Hematology

Table 3.

Prognostic factors other than cell dose influencing outcome, P (log-rank test)

	LFS	RI	TRM	OS
Patient sex	.91	.89	.78	.53
Donor sex	.86	.1	.09	.68
Female to male	.54	.1	.02†	.15
FAB M5 versus other	.88	.83	.98	.7
TBI	.72	.79	.48	.57
Patient age	.06	.86	.007†	.02†
Donor age	.009†	.28	.01†	.012†
Year of transplantation (before 1997 versus after 1997)	.26	.16	.79	.92
Interval diagnosis-CR1, d	.08	.88	.03†	.02†
Interval CR1-transplantation, d	.16	.52	.02†	.14
White blood cell count at diagnosis	.94	.82	.77	.51
Center*	.02†	.22	.03	.01†

	LFS	RI	TRM	OS
Patient sex	.91	.89	.78	.53
Donor sex	.86	.1	.09	.68
Female to male	.54	.1	.02†	.15
FAB M5 versus other	.88	.83	.98	.7
TBI	.72	.79	.48	.57
Patient age	.06	.86	.007†	.02†
Donor age	.009†	.28	.01†	.012†
Year of transplantation (before 1997 versus after 1997)	.26	.16	.79	.92
Interval diagnosis-CR1, d	.08	.88	.03†	.02†
Interval CR1-transplantation, d	.16	.52	.02†	.14
White blood cell count at diagnosis	.94	.82	.77	.51
Center*	.02†	.22	.03	.01†

One class grouping all centers performing fewer than 10 transplantations during the period.

Significant difference.